Loading financial data...

4D Molecular Therapeutics, Inc. (FDMT) Financial Statements | Global Financial Data

4D Molecular Therapeutics, Inc.

FDMTSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1650648

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	$20.7M	$3.1M	$18.0M	$13.4M	$7.0M
Operating Expenses	$133.6M	$113.2M	$89.4M	$70.3M	$57.8M
Operating Income (Loss)	-$112.9M	-$110.0M	-$71.3M	-$56.7M	-$50.8M
Nonoperating Income (Expense)	$12.0M	$2.5M	$16.0K	-$29.0K	$1.5M
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00	—
Net Income (Loss) Attributable to Parent	-$100.8M	-$107.5M	-$71.3M	-$56.7M	-$49.3M
Earnings Per Share, Basic	-$2.58	-$3.32	-$2.57	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$339.9M	$261.8M	$353.5M	$288.3M	$58.2M
Assets, Current	$296.6M	$220.5M	$256.3M	$282.7M	$52.5M
Cash and Cash Equivalents, at Carrying Value	$249.1M	$52.4M	$153.0M	$276.7M	$49.7M
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	$47.0K	$1.5M	$978.0K
Liabilities	$32.1M	$30.5M	$34.4M	$31.9M	$28.2M
Liabilities, Current	$19.0M	$15.7M	$16.3M	$16.7M	$13.0M
Accounts Payable, Current	$3.5M	$3.3M	$4.8M	$1.8M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$75.8M	-$86.7M	-$69.1M	-$50.9M	-$36.7M
Net Cash Provided by (Used in) Investing Activities	$115.7M	-$17.1M	-$172.7M	-$1.0M	-$3.2M
Net Cash Provided by (Used in) Financing Activities	$156.8M	$3.1M	$118.1M	$279.0M	-$2.2M
Payments to Acquire Property, Plant, and Equipment	$2.8M	$11.5M	$9.1M	$1.0M	$3.2M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)